AEON Biopharma has closed an underwritten public offering of common stock, pre-funded warrants, and accompanying milestone warrants, raising net proceeds of approximately $12.2 million. The company intends to use the funds for working capital and to advance clinical development, including testing to support biosimilarity of its lead candidate, ABP-450, to BOTOX®.
Key Details
- Net Proceeds: The company received approximately $12.2 million in net proceeds after deducting underwriting discounts, commissions, and other offering expenses.
- Offering Structure: The offering included 17,851,599 shares of common stock at $0.3221 per share and pre-funded warrants to purchase 24,837,008 shares at $0.3220 per warrant. Each share and pre-funded warrant was sold with one two-year and one five-year milestone warrant.
- Use of Funds: Proceeds are allocated for working capital and general corporate purposes, specifically including funding for comparative analytical testing on ABP-450.
- Timeline: The underwriting agreement was signed on July 13, 2026, and the offering closed on July 15, 2026.